---
title: "Savara Inc. (SVRA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/SVRA.US.md"
symbol: "SVRA.US"
name: "Savara Inc."
industry: "Biotechnology"
---

# Savara Inc. (SVRA.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.savarapharma.com](https://www.savarapharma.com) |

## Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar p...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -10.06 | 448/604 | - | - | - |
| PB | 12.33 | 385/604 | 12.07 | 5.40 | 3.25 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-27T05:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 6 | 75% |
| Overweight | 2 | 25% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.53 |
| Highest Target | 16.00 |
| Lowest Target | 9.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/SVRA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/SVRA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/SVRA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.